STOCKS TELEGRAPH

Tag: HCWB

  • Here’s the Reason of Growing Premarket Stock of HCW Biologics Inc. (HCWB).

    Here’s the Reason of Growing Premarket Stock of HCW Biologics Inc. (HCWB).

    HCW Biologics Inc. (HCWB) is an immunotherapy company engaged in the treatment of inflammation or chronic, low-grade inflammation and age-related diseases such as oncological disorders, diabetes, cardiovascular, neurodegenerative, and autoimmune diseases. The pipeline candidates of the company include HCW9218 for treating pancreatic cancer and HCW9302 for autoimmune disorders.

    The price of HCWB stock during the regular trading on January 21, 2022, was $2.02 with a steep 12.55% decrease. At last check in the premarket on January 24, 2022, the stock was significantly up by 4.95%.

    HCWB: Events and Happenings

    On January 24, 2022, HCWB reported about clearance by FDA for the Masonic Cancer Center for proceedings to assess HCW9218’s Phase 1 trial in solid tumor patients. The lead pipeline candidate of the company is an injectable, bifunctional fusion protein complex used to gear anti-tumor activity.

    On January 20, 2022, HCWB reported about its research paper publication in Molecular Therapy titled ‘Immunotherapeutic HCW9218 enhances the anti-tumor activity of chemotherapy via NK cell-mediated reduction of therapy-induced senescent cells.’

    On January 19, 2022, the company reported that its Executives presented at the 24th Annual PepTalk Virtual Conference by Cambridge Healthtech Institute held on January 17-19, 2022. On January 06, 2022, HCWB reported that the company’s Executives presented at the H.C. Wainwright BioConnect Conference held on January 10 – 13, 2022.

    On December 13, 2021, HCWB reported that the company’s CEO Hing C. Wong was nominated by BioFlorida as the 2021 Entrepreneur of the Year.

    HCWB: Key Financials

    On November 12, 2021, HCWB reported its financial results for its third quarter ended September 30, 2021. Some of the key updates are as follows.

    Net Loss per Share

    Basic and diluted net loss in Q3 2021 was $4.1 million or $0.14 per share compared to $2.7 million or $0.63 per share in the same period of 2020.

    Assets

    Total current assets of the company in Q3 2021 were recorded to be $12.1 million.

    Conclusion

    HCWB stock dipped by 62% from the last half-year as a result of pandemic and slow economic growth. The current premarket rise in the company’s stock is due to the clearance received by the FDA. The analysts are suggesting that the company is outperforming in all the sectors despite the restrictions put by the pandemic.

  • HCW Biologics Inc. (HCWB) stock gained in the current market; here is why?

    The stock of HCW Biologics Inc. (HCWB) gained in the current market after announcing its publication of a research paper in the journal Molecular Therapy. HCWB values at around $2.25, gaining more than 8% from the previously closed value. At the end of the last trading session, the stock closed at $2.07. The stock’s traded volume in the previous trading session was around 108.18K shares.

    Reasons for HCWB stock gain

    Today, on January 20, 2022, HCW Biologics Inc. (HCWB) announced the publication of a scientific paper by its scientific research team in the journal Molecular Therapy. The research paper aims to show that the company’s lead investigational candidate, HCW9218, can enhance the anti-tumor efficacy of chemotherapy drugs. It reduces therapy-induced senescence (TIS) to minimize the side effects.

    Cellular senescence is vital in reducing a tumor, but the evidence is clear that standard cancer treatments like chemotherapy and radiation cause senescent cell accumulation in normal and tumor tissue. Senescence defends non-dividing cancer cells from chemotherapeutic drugs and radiation. It also contributes to relapse, chemoresistance, and other side effects. This publication shows that HCW9218 can significantly reduce cellular senescence caused by current chemotherapy, enhancing anti-tumor effectiveness and reducing side effects.

    The FDA approved the HCW Biologics Inc. (HCWB) first-in-human Phase 1b clinical trial of HCW9218 in patients with severe pancreatic cancer in October 2021. A second investigator-initiated trial evaluating HCW9218 in patients with breast, ovarian, prostate, colorectal, and other solid tumors is also being discussed with a research facility.

    The effect on the stock gain

    The publication had a substantial effect on the stock of the company. The stock surged in the current market due to the positive results delivered by the company. The approval from the FDA gives it further acknowledgment due to which the stock of HCW Biologics Inc. (HCWB) was in high demand, and its stock soared.

    Conclusion

    HCW Biologics Inc. (HCWB) stock is gaining after its massive success in the study conducted. It is also approved by the FDA, which means it will bring a new revenue stream for the company. The company’s outlook for the future shows focusing on trials to evaluate the HCW9218 effect on patients with different cancers.